Clinical trials: Cohort
Congenital Adrenal Hyperplasia, Classic Congenital Adrenal Hyperplasia
Evaluate the Safety, Efficacy, and Pharmacokinetics of CRN04894 in Participants With Congenital Adrenal Hyperplasia (TouCAHn)
The purpose of this Phase 2, open-label, sequential dose cohort study is to evaluate the safety, efficacy, and pharmacokinetics (PK) of atumelnant (CRN04894) in participants with classic congenital adrenal hyperplasia (CAH)…
- Trial name
- NCT05907291
- Testing
- atumelnant (CRN04894)
- Where
- 27 sites in United States, Argentina and 5 more
- Volunteers
- 38 people
- Sponsor
- Crinetics Pharmaceuticals Inc.
Advanced Solid Tumors
A Study of E7050 in Combination With E7080 in Participants With Advanced Solid Tumors (Dose Escalation) and in Participants With Recurrent Glioblastoma or Unresectable Stage III or Stage IV Melanoma After Prior Systemic Therapy (Expansion Cohort and Phase 2)
This is a multicenter, open-label, Phase 1b/2 study which will be conducted in two parts: a Phase 1b part comprising a dose escalation and an expansion cohort; and a Phase 2 part which will comprise two cohorts.
- Trial name
- NCT01433991
- Testing
- Golvatinib, Lenvatinib
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Eisai Inc.
Hepatitis C
Japanese Pegylated Interferon (PegIFN) Alfa-2b/Ribavirin (RBV) Combination Trial
The aim of this trial is to evaluate the safety and efficacy of BI 201335 given for 12 or 24 weeks in combination with PegIFN alfa-2b/RBV given for 24 or 48 weeks in chronic genotype 1 hepatitis C virus infected treatment-naïve…
- Trial name
- NCT01579474
- Testing
- BI 201335 high dose, BI 201335 low dose
- Where
- 24 sites in Japan
- Volunteers
- 131 people
- Sponsor
- Boehringer Ingelheim
Solid Tumor, Osteosarcoma
Metronomic Chemotherapy in Patients With Advanced Solid Tumor With Bone Metastasis and Advanced Pretreated Osteosarcoma
This is a prospective open-labeled phase I trial based on a dose escalating study design assessing two dose levels of sirolimus when prescribed in combination with metronomic cyclophosphamide (CP), methotrexate (MT) and…
- Trial name
- METZOLIMOS (NCT02517918)
- Testing
- Sirolimus combined with CP, MT and ZA
- Where
- 3 sites in France
- Volunteers
- 23 people
- Sponsor
- Institut Bergonié
Major and Minor Surgical Complications
Impact of Opioid Free Anesthesia on Outcome After DIEPflap Surgery
The Deep Inferior Epigastric Perforator free flap (DIEPflap) involves the transfer of abdominal tissue to the breast using microsurgery. Flap failure is rare today, but is devastating.
- Trial name
- DIEPflap (NCT03202134)
- Testing
- opioid free anesthesia
- Where
- Belgium
- Volunteers
- 204 people
- Sponsor
- AZ Sint-Jan AV
Raynaud's Disease, Peripheral Vascular Disease
PF-00489791 For The Treatment Of Raynaud's
The investigators propose that once daily administration of PF-00489791, a phosphodiesterase inhibitor, will reduce vasospasm and improve symptoms and signs associated with Primary and Secondary Raynaud's Phenomenon.
- Trial name
- NCT01090492
- Testing
- PF-00489791
- Where
- 55 sites in United States, Canada and 9 more
- Volunteers
- 243 people
- Sponsor
- Pfizer
Contraception
Comparison of the Levonorgestrel IUD and the Copper IUD Placed in the Immediate Postplacental Period: A Prospective Cohort Study
The intrauterine device (IUD) is a safe, highly effective, long acting, and reversible form of contraception. The postpartum period is an important moment for contraceptive intervention; however there are many barriers to women…
- Trial name
- NCT02067663
- Testing
- Paragard, Mirena
- Where
- United States
- Volunteers
- 123 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Stress, Psychological
The Impact of 8 Weeks of Digital Meditation Application and Healthy Eating Program on Work Stress and Health Outcomes
The aim of the present study is to test the effects of a digital meditation intervention and/or a healthy eating intervention in a sample of UCSF employees with overweight and obesity (BMI>=25kg/m2) who report mild to moderate…
- Conditions
- Stress, Psychological, Behavioral Symptoms, Sleep
- Trial name
- SFUC+Health (NCT03945214)
- Testing
- Meditation, Healthy Eating, Meditation + healthy eating
- Where
- United States
- Volunteers
- 163 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Treatment Resistant Depression
Stanford Accelerated Intelligent Neuromodulation Therapy for Treatment-Resistant Depression: OL Cohort
This study evaluates an accelerated schedule of theta-burst stimulation using a transcranial magnetic stimulation device for treatment-resistant depression.
- Trial name
- SAINT-TRD (NCT03240692)
- Testing
- Accelerated theta-burst stimulation treatment
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Stanford University
Tracheostomy, Communication
A Speech Recognition Application as a Communication Aid for Acute and Critical Care Patients With Tracheostomies
Patients in acute and critical care often undergo a tracheostomy. A tracheostomy is an incision at the front of the neck to insert a breathing tube directly into the airway.
- Conditions
- Tracheostomy, Communication, Acute/Critical Illness
- Trial name
- SRAVI (NCT06027866)
- Testing
- SRAVI (Speech Recognition Application for the Voice Impaired)
- Where
- United Kingdom
- Volunteers
- 31 people
- Sponsor
- Queen's University, Belfast
Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma
Bendamustine Bridge to Autologous or Allogeneic Transplant for Relapsed/Refractory Lymphoma
This clinical trial is for men and women with whose lymphoma (non-Hodgkin or Hodgkin) did not respond to treatment or has returned after responding to previous therapy, and who are in need of a stem cell transplant.
- Trial name
- NCT02059239
- Testing
- Bendamustine, Carmustine, Etoposide
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Weill Medical College of Cornell University
COVID-19
A Real World Study of Bamlanivimab in Participants With Mild-to-Moderate Coronavirus Disease 2019 (COVID-19)
The purpose of this study is to find out whether bamlanivimab is able to stop COVID-19 from getting worse. Participants with mild-to-moderate COVID-19 will receive bamlanivimab via an injection into a vein.
- Trial name
- BLAZE-5 (NCT04701658)
- Testing
- Bamlanivimab
- Where
- United States
- Volunteers
- 109 people
- Sponsor
- Eli Lilly and Company
Venous Thromboembolism
Prevention of Venous Thromboembolic Events After Elective Orthopaedic Surgery in Patients Treated With PRADAXA
Observational cohort study on the prevention of venous thromboembolic events after elective orthopaedic surgery for Total Knee Replacement or Total Hip Replacement iin patients treated with PRADAXA to evaluate the efficacy ant…
- Trial name
- NCT01139658
- Where
- 53 sites in France
- Volunteers
- 1,676 people
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
Cardiovascular Events in Chronic Obstructive Pulmonary Disease Patients Initiating Olodaterol or Other Long-acting beta2 Agonists
Examine the risk of cardiovascular events (cardiac arrhythmia or myocardial ischemia) or all-cause mortality in Chronic Obstructive Pulmonary Disease (COPD) patients who are new users of Olodaterol or other LABAs available for…
- Trial name
- NCT03405363
- Where
- Denmark
- Volunteers
- 65,406 people
- Sponsor
- Boehringer Ingelheim
Coronary Disease
RE-DEEM Dose Finding Study for Dabigatran Etexilate in Patients With Acute Coronary Syndrome
The purpose of this trial is to evaluate the safety and indicators of efficacy of up to 4 doses of orally administered dabigatran etexilate, administered twice daily, compared to placebo when given in addition to dual…
- Trial name
- NCT00621855
- Testing
- dabigatran etexilate
- Where
- 167 sites in United States, Belgium and 22 more
- Volunteers
- 1,878 people
- Sponsor
- Boehringer Ingelheim
Thrombocytopenia, Hematologic Diseases
Thrombosomes® in Bleeding Thrombocytopenic Patients
The study evaluates the safety and potential early signals of efficacy of allogeneic Thrombosomes in bleeding thrombocytopenic patients
- Conditions
- Thrombocytopenia, Hematologic Diseases, Bone Marrow Aplasia
- Trial name
- NCT03394755
- Testing
- Thrombosomes
- Where
- 7 sites in United States, Norway
- Volunteers
- 24 people
- Sponsor
- Cellphire Therapeutics, Inc.
Stroke, Ischemic, Inflammatory Response
TSPO PET as a Measure of Post-stroke Brain Inflammation: a Natural History Cohort
DESIGN: exploratory, prospective, natural history, imaging cohort study BACKGROUND: Stroke causes a strong inflammatory response in the brain which is thought to contribute to permanent brain damage in stroke patients.
- Conditions
- Stroke, Ischemic, Inflammatory Response, Stroke, Acute
- Trial name
- NCT03662750
- Testing
- Brain Imaging
- Where
- United Kingdom
- Volunteers
- 3 people
- Sponsor
- Imperial College London
Child, Preschool, Child
Monitoring Activity And Gait In Children
COHORT A: To study whether a digital health tool called Actigraph can be used to collect information on gait and physical activity in healthy children aged 3-17.
- Conditions
- Child, Preschool, Child, Adolescent
- Trial name
- MAGIC (NCT04823650)
- Testing
- COHORT A: Actigraph, Panoramic Bracelet and GENEActiv
- Where
- United States
- Volunteers
- 87 people, healthy volunteers welcome
- Sponsor
- Pfizer
Thyroid Cancer
Nivolumab Plus Ipilimumab in Thyroid Cancer
This research study is studying nivolumab, an investigational drug, in combination with ipilimumab, also an investigational drug, as a possible treatment for thyroid cancer.
- Trial name
- NCT03246958
- Testing
- Nivolumab, Ipilimumab
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- Dana-Farber Cancer Institute
Sickle Cell Disease
European Sickle Cell Disease Cohort - Hydroxyurea
In the context of the Risk Management Plan (RMP), as requested from Addmedica by the EMEA, to collect information about long-term safety of Siklos® (hydroxycarbamide) when used in patients with Sickle Cell Disease.
- Trial name
- ESCORT-HU (NCT02516579)
- Testing
- Siklos
- Where
- 60 sites in France, French Guiana and 5 more
- Volunteers
- 1,906 people
- Sponsor
- Theravia